From FDA actions to new standard-of-care potential, the breast cancer treatment arsenal continues to expand. This week’s news ...

“Oncology nurses are unique in that we see patients for a long time. We get to know their families. We see them through graduation, through weddings, progression of disease, recurrence,” said ...

Data from the COMMIT trial demonstrated that the addition of oxaliplatin, leucovorin, 5-fluorouracil (mFOLFOX6) and ...

About 15,000 registered nurses at several of New York City’s major hospitals walked off the job Jan 12 after contract ...

When a patient with renal cell carcinoma (RCC) progresses on or following the combination of a tyrosine kinase inhibitor (TKI ...

We’re starting to understand more that endometrial cancer harbors a number of cell surface markers, including folate receptor ...

As the renal cell carcinoma (RCC) treatment landscape shifts to more personalized and combinatorial approaches, advanced practice providers (APPs) are key to the safety of patients receiving tyrosine ...

Data from the longitudinal ColoCare study (NCT02328677) of patients with colorectal cancer add to a growing body of evidence ...

Transportation is a key accessibility issue for patients with HR-positive metastatic breast cancer receiving CDK4/6 inhibitors at community clinics.

Findings from a real-world, head-to-head comparison show greater colorectal cancer risk reduction and safety with the use of a GLP-1RA vs aspirin.

Deborah (Debi) A. Boyle MSN, RN, AOCNS, FAAN, is editor in chief of Oncology Nursing News®. She is a long tenured oncology clinical nurse specialist who has practiced in both Comprehensive Cancer ...